FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2528289968> ?p ?o ?g. }

• W2528289968 endingPage "104" @default.
• W2528289968 startingPage "103" @default.
• W2528289968 abstract "Routine prophylaxis is recommended to prevent venous thromboembolism (VTE) – manifesting as deep vein thrombosis (DVT) and/or pulmonary embolism (PE) – in patients undergoing major orthopaedic surgery. Rivaroxaban (BAY 59-7939) is a novel, oral, direct Factor Xa inhibitor in development for the prevention and treatment of VTE. The efficacy and safety of 5–9 days’ prophylaxis with rivaroxaban were investigated in three randomized, double-blind, phase IIb trials in patients undergoing elective, total hip or knee replacement (THR or TKR), relative to subcutaneous enoxaparin. Two trials (one in patients undergoing THR, N=722; and one in patients undergoing TKR, N=621) investigated twice-daily (bid) rivaroxaban (at total daily doses of 5–60 mg); the third (in patients undergoing THR, N=873) investigated once-daily (od) rivaroxaban (at doses of 5, 10, 20, 30 or 40 mg od). Rivaroxaban – at all doses tested – had similar efficacy to enoxaparin in the bid trials. This promising finding was strengthened by the od trial, in which the observed incidences of the primary efficacy endpoint (DVT, non-fatal PE or all-cause mortality) were lower in patients receiving rivaroxaban 5, 10, 20, 30 and 40 mg od (14.9%, 10.6%, 8.5%, 13.5% and 6.4%, respectively) than enoxaparin (25.2%). Although there was no significant dose–response relationship between rivaroxaban and the primary efficacy endpoint in these trials, there was with major VTE (proximal DVT, PE or VTE-related death; p=0.0072) in the od trial (incidences were 8.5%, 2.7%, 0.9%, 1.9% and 1.1% with rivaroxaban 5, 10, 20, 30 and 40 mg od, respectively, vs 2.8% with enoxaparin). Significant dose–response relationships between rivaroxaban and major bleeding were observed in all three trials. In the bid trials, major bleeding rates with rivaroxaban were similar to those with enoxaparin at total daily doses of 5–20 mg. In the od trial, major bleeding occurred in 2.3%, 0.7%, 4.3%, 4.9% and 5.1% of patients receiving rivaroxaban 5, 10, 20, 30 and 40 mg od, respectively, and in 1.9% of those receiving enoxaparin. Rivaroxaban was generally well tolerated in the bid and od trials, and the incidence of nausea and vomiting with early post-operative oral rivaroxaban administration was low for all doses tested. The bid trials suggest that oral rivaroxaban at total daily doses of 5–20 mg may be a safe and effective alternative to enoxaparin for the prevention of VTE after major orthopaedic surgery. The od trial suggests that the more-convenient od regimen is feasible and that 10 mg od, a dose within the range identified by the bid trials, should be investigated further. As a result, oral rivaroxaban 10 mg od is currently being investigated in four phase III trials for the prevention of VTE after major orthopaedic surgery (the RECORD trials)." @default.
• W2528289968 created "2016-10-14" @default.
• W2528289968 creator A5012512308 @default.
• W2528289968 creator A5039463274 @default.
• W2528289968 creator A5058039245 @default.
• W2528289968 creator A5061119795 @default.
• W2528289968 creator A5061240133 @default.
• W2528289968 creator A5067500850 @default.
• W2528289968 creator A5074067891 @default.
• W2528289968 creator A5083647812 @default.
• W2528289968 creator A5088406700 @default.
• W2528289968 date "2009-03-01" @default.
• W2528289968 modified "2023-09-24" @default.
• W2528289968 title "RIVAROXABAN (BAY 59-7939) – A NOVEL, ORAL, DIRECT FACTOR XA INHIBITOR – FOR PREVENTION OF VENOUS THROMBOEMBOLISM AFTER MAJOR ORTHOPAEDIC SURGERY: OVERVIEW OF THREE PHASE II TRIALS" @default.
• W2528289968 hasPublicationYear "2009" @default.
• W2528289968 type Work @default.
• W2528289968 sameAs 2528289968 @default.
• W2528289968 citedByCount "0" @default.
• W2528289968 crossrefType "journal-article" @default.
• W2528289968 hasAuthorship W2528289968A5012512308 @default.
• W2528289968 hasAuthorship W2528289968A5039463274 @default.
• W2528289968 hasAuthorship W2528289968A5058039245 @default.
• W2528289968 hasAuthorship W2528289968A5061119795 @default.
• W2528289968 hasAuthorship W2528289968A5061240133 @default.
• W2528289968 hasAuthorship W2528289968A5067500850 @default.
• W2528289968 hasAuthorship W2528289968A5074067891 @default.
• W2528289968 hasAuthorship W2528289968A5083647812 @default.
• W2528289968 hasAuthorship W2528289968A5088406700 @default.
• W2528289968 hasConcept C126322002 @default.
• W2528289968 hasConcept C141071460 @default.
• W2528289968 hasConcept C168563851 @default.
• W2528289968 hasConcept C203092338 @default.
• W2528289968 hasConcept C2776265017 @default.
• W2528289968 hasConcept C2776301958 @default.
• W2528289968 hasConcept C2778661090 @default.
• W2528289968 hasConcept C2778959117 @default.
• W2528289968 hasConcept C2779161974 @default.
• W2528289968 hasConcept C2780868729 @default.
• W2528289968 hasConcept C42219234 @default.
• W2528289968 hasConcept C535046627 @default.
• W2528289968 hasConcept C71924100 @default.
• W2528289968 hasConceptScore W2528289968C126322002 @default.
• W2528289968 hasConceptScore W2528289968C141071460 @default.
• W2528289968 hasConceptScore W2528289968C168563851 @default.
• W2528289968 hasConceptScore W2528289968C203092338 @default.
• W2528289968 hasConceptScore W2528289968C2776265017 @default.
• W2528289968 hasConceptScore W2528289968C2776301958 @default.
• W2528289968 hasConceptScore W2528289968C2778661090 @default.
• W2528289968 hasConceptScore W2528289968C2778959117 @default.
• W2528289968 hasConceptScore W2528289968C2779161974 @default.
• W2528289968 hasConceptScore W2528289968C2780868729 @default.
• W2528289968 hasConceptScore W2528289968C42219234 @default.
• W2528289968 hasConceptScore W2528289968C535046627 @default.
• W2528289968 hasConceptScore W2528289968C71924100 @default.
• W2528289968 hasLocation W25282899681 @default.
• W2528289968 hasOpenAccess W2528289968 @default.
• W2528289968 hasPrimaryLocation W25282899681 @default.
• W2528289968 hasRelatedWork W2204301525 @default.
• W2528289968 hasRelatedWork W2260550369 @default.
• W2528289968 hasRelatedWork W2336189836 @default.
• W2528289968 hasRelatedWork W2341853134 @default.
• W2528289968 hasRelatedWork W2402165226 @default.
• W2528289968 hasRelatedWork W2525269057 @default.
• W2528289968 hasRelatedWork W2528173524 @default.
• W2528289968 hasRelatedWork W2529006396 @default.
• W2528289968 hasRelatedWork W2530861981 @default.
• W2528289968 hasRelatedWork W2533920607 @default.
• W2528289968 hasRelatedWork W2537140903 @default.
• W2528289968 hasRelatedWork W2547742335 @default.
• W2528289968 hasRelatedWork W2562530087 @default.
• W2528289968 hasRelatedWork W2566840902 @default.
• W2528289968 hasRelatedWork W2592970357 @default.
• W2528289968 hasRelatedWork W2890236754 @default.
• W2528289968 hasRelatedWork W2979415664 @default.
• W2528289968 hasRelatedWork W2982464050 @default.
• W2528289968 hasRelatedWork W3171770197 @default.
• W2528289968 hasRelatedWork W2563765239 @default.
• W2528289968 isParatext "false" @default.
• W2528289968 isRetracted "false" @default.
• W2528289968 magId "2528289968" @default.
• W2528289968 workType "article" @default.